Our thought leadership initiatives are highly customized. We seek out high-ROI speaking engagements and opportunities. We offer editorial guidance on company and executive blogs. And we place op/eds from your C-suite in outlets that reach your core audiences.
This is an exciting time to be developing cell therapies as the field is reaching an inflection point that can lead to a major improvement in the lives of patients. Just as the approval of CAR T cell therapies have provided a new treatment for patients in recent years, we believe that we’re on the cusp of delivering a powerful and potentially curative cell therapy to patients that can revolutionize the field of bone marrow transplant.
HSC gene therapy specifically holds great promise against otherwise intractable diseases, due to its advantages of potential durability and ability for gene-modified HSCs to differentiate into multiple new cell types and migrate and deliver genes into multiple different organ systems and tissues. I believe there’s a very exciting future ahead for the application of HSC gene therapy in a growing range of indications.
I’ve told the management team that I believe in telling it like it is. I don’t like to sugar-coat or dance around a topic: I believe in honest, straightforward communication. Only then can you feel confident your team truly understands your message – and will stand behind you in both the banner moments and the more difficult times.
Treating and abating COVID-19 has become everyone’s top priority. However, critical health care needs like treatments for cancer and rare genetic diseases still remain essential — and it’s our responsibility in the cell therapy industry to formulate the processes to deliver them.
Karen Akinsanya
Senior Vice President & Chief Biomedical Scientist, Schrödinger
Featuring Yasir Al-Wakeel, CFO, Neon Therapeutics
We [arranged] seating by cross-functional teams, with teams focused on advancing our therapeutic candidates for liver disorders grouped together in one area, and those focused on retinal disorders collaborating closely in another. We have no group seating defined by hierarchy or function; instead, scientists, leadership team members, administrators and program team members are all mixed together throughout the floor plan.
When scientists unlocked the human genome, they opened a new door to game-changing medicine. I believe that translating genomic insights into innovative treatments is one of our greatest opportunities to dramatically transform patients’ lives and the healthcare industry. But I also believe that there’s a fundamental misalignment between this century’s scientific discoveries and the financial incentives built into our healthcare system.
Carolyn Bertozzi, professor of chemistry, Stanford University and co-founder, Palleon Pharmaceuticals
